SUZANNE FRYE: Open Payments
NPI 1922449917 · SHREVEPORT, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$351 in 20 payments from 9 companies in 2025. Trend: 2023 $87 · 2024 $235 · 2025 $351
Food & beverage: $351
| Company | Payments | Amount |
|---|---|---|
| PFIZER INC. | 5 | $84 |
| Dexcom, Inc. | 3 | $68 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $57 |
| Lilly USA, LLC | 3 | $47 |
| Novo Nordisk Inc | 2 | $30 |
| Otsuka America Pharmaceutical, Inc. | 1 | $20 |
| Viatris Specialty LLC | 1 | $16 |
| Phathom Pharmaceuticals, Inc. | 1 | $15 |
| GlaxoSmithKline, LLC. | 1 | $15 |
Products named: ELIQUIS, Dexcom G6 Transmitter, MOUNJARO, REXULTI, YUPELRI, Ozempic, VOQUEZNA, Wegovy.
Industry payments across LA — which companies pay providers there.
